8-K: MIRA Pharmaceuticals Announces Ketamir-2 Shows No Brain Toxicity in FDA-Required Study

MIRA Pharmaceuticals reports that Ketamir-2, its novel oral NMDA receptor antagonist, did not induce neurotoxic changes in a regulatory-required study, confirming the absence of ketamine-linked neurotoxicity.

Summary

• MIRA Pharmaceuticals announced the completion of an FDA-required neurotoxicity study of Ketamir-2 on May 6, 2025.
• The study aimed to evaluate the potential of Ketamir-2 to cause neuropathologic changes, including Olney lesions, which are associated with NMDA receptor antagonists like ketamine.
• The study was conducted on sexually mature Sprague-Dawley rats, with high oral doses of Ketamir-2 administered to one group and MK-801 to a positive control group.
• The study found no test article-related mortality or adverse clinical signs in animals treated with Ketamir-2.
• No microscopic or macroscopic brain lesions were detected in the Ketamir-2-treated groups.
• The positive control group treated with MK-801 showed clear evidence of vacuolation and neuronal necrosis, consistent with Olney-type lesions.
• The results indicate that Ketamir-2 did not induce neurotoxic changes under the study conditions.
• These findings will be submitted to the FDA as part of MIRA's ongoing regulatory communications.

Sentiment

Score: 8

Explanation: The document presents positive news regarding the safety profile of Ketamir-2, which is a key factor in its potential for future development and approval. The absence of neurotoxicity is a significant advantage.

Positives

• Ketamir-2 did not induce neurotoxic changes in the study.
• There were no adverse clinical signs or mortality in animals treated with Ketamir-2.
• The absence of brain lesions in the Ketamir-2 group is a positive sign for its safety profile.
• The positive control group showed expected results, validating the study's methodology.

Risks

• The study was conducted on animals, and further clinical trials in humans are needed to confirm these findings.
• The FDA may require additional studies or data before approving Ketamir-2.

Future Outlook

MIRA Pharmaceuticals plans to submit the study results to the FDA as part of its ongoing regulatory communications, suggesting continued progress towards potential approval of Ketamir-2.

Management Comments

• Erez Aminov, Chief Executive Officer, signed the report on behalf of MIRA Pharmaceuticals.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly companies developing drugs targeting NMDA receptors. The absence of neurotoxicity is a significant advantage for Ketamir-2 compared to other NMDA receptor antagonists like ketamine, which have known neurotoxic effects.

Comparison to Industry Standards

• Ketamine, a known NMDA receptor antagonist, has been associated with neurotoxic effects, including Olney lesions.
• The study's positive control group, treated with MK-801 (another NMDA receptor antagonist), showed clear evidence of Olney-type lesions, consistent with known effects.
• The absence of such lesions in the Ketamir-2 group suggests a potentially safer profile compared to ketamine and MK-801.

Stakeholder Impact

• The positive safety data could increase investor confidence in MIRA Pharmaceuticals.
• The potential for a safer NMDA receptor antagonist could benefit patients in need of such treatments.

Next Steps

• MIRA Pharmaceuticals will submit the study results to the FDA.
• The company will continue its ongoing regulatory communications with the FDA.

Key Dates

Keywords

Ketamir-2, MIRA Pharmaceuticals, Neurotoxicity, NMDA receptor antagonist, FDA, Olney lesions, MK-801, Clinical development